Groupama Asset Management’s AstraZeneca AZN Stock Holding History

Groupama Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$125M	Buy	873,930 +10,301	+1%	+$1.94M	1.57%	19
2026 Q1	$127M	Buy	+863,629	New	+$167M	1.85%	16
2024 Q4	–	Sell	-271,699	Closed	-$67.8M	–	413
2024 Q3	$67.8M	Buy	271,699 +50,612	+23%	+$8.17M	1.76%	11
2024 Q2	$68.7M	Buy	221,087 +28,590	+15%	+$4.3M	0.93%	25
2024 Q1	$51.9M	Buy	+192,497	New	+$25.5M	0.95%	26

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Groupama Asset Management's AZN Position: Q2 2026 in Review

Groupama Asset Management increased its AstraZeneca (AZN) stake by 1.2% in Q2 2026, buying an estimated $1.94M and bringing the position to 873,930 shares worth $125M. The position accounts for 1.57% of the portfolio, ranked #19.

Groupama Asset Management first reported a position in AZN in Q1 2024 and has held it in 5 quarters since. The position peaked at $127M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Groupama Asset Management held 873,930 shares of AstraZeneca worth $125M as of Q2 2026.
Groupama Asset Management bought 10,301 AstraZeneca shares in Q2 2026, an estimated $1.94M.
AstraZeneca made up 1.57% of Groupama Asset Management's portfolio in Q2 2026, its #19 holding.
Groupama Asset Management first reported a position in AstraZeneca in Q1 2024 and has held it in 5 quarters since.
Groupama Asset Management's AstraZeneca position peaked at $127M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Groupama Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.